Last updated: November 9, 2026
TRODELVY generated about $1.1 billion in 2024 sales, up from $1.0 billion in 2023 and $680 million in 2022. Gilead Sciences acquired the product through its $21 billion purchase of Immunomedics in 2020. The commercial opportunity remains substantial in metastatic breast cancer, but growth depends on earlier-line adoption, differentiation against AstraZeneca and Daiichi Sankyo's Enhertu, and success in additional solid-tumor indications. The withdrawal of the urothelial-cancer indication weakened the near-term expansion case, while biologic exclusivity and complex antibody-drug-conjugate manufacturing limit immediate biosimilar risk.
How much revenue does TRODELVY generate?
TRODELVY is one of Gilead's largest non-HIV products. Reported product sales have increased significantly since the 2020 acquisition.
| Fiscal year |
TRODELVY product sales |
Year-over-year growth |
Approximate share of Gilead product sales |
| 2021 |
$380 million |
Not comparable |
Approximately 1.5% |
| 2022 |
$680 million |
79% |
Approximately 2.5% |
| 2023 |
$1.045 billion |
54% |
Approximately 3.9% |
| 2024 |
Approximately $1.1 billion |
Low-single-digit growth |
Approximately 3.8% |
Sources: Gilead Sciences annual reports and fourth-quarter earnings disclosures.[1-4]
The product reached blockbuster status in 2023. Growth then slowed in 2024 as the metastatic triple-negative breast-cancer market became more competitive and the product's urothelial-cancer indication was withdrawn.
TRODELVY remains financially important because its gross margin profile is materially stronger than that of a typical small-molecule product. Its revenue base also gives Gilead an oncology platform around which it can develop combinations and additional indications. The product has not yet approached the revenue scale of Gilead's HIV franchise, which generated more than $18 billion in 2024, but it has become a meaningful contributor to the company's diversification strategy.[4]
What is the financial trajectory for TRODELVY?
The revenue trajectory has three phases.
2020 to 2022: launch and rapid penetration
Gilead acquired Immunomedics in October 2020. The transaction gave Gilead full control of sacituzumab govitecan, the antibody-drug conjugate marketed as TRODELVY, along with the Immunomedics development organization and intellectual property portfolio.
Sales increased from $380 million in 2021 to $680 million in 2022. The principal driver was demand in metastatic triple-negative breast cancer, where treatment options were limited and TRODELVY had an established position after prior chemotherapy.
2023: expansion into hormone-receptor-positive breast cancer
The FDA granted accelerated approval in February 2023 for TRODELVY in adults with unresectable locally advanced or metastatic hormone-receptor-positive, HER2-negative breast cancer who had received endocrine-based therapy and at least two additional systemic treatments.[5]
The approval expanded the addressable population beyond triple-negative disease. Gilead reported 2023 sales of $1.045 billion, reflecting increased use in breast cancer and continued international rollout.[2]
2024 onward: slower growth and indication pressure
Revenue growth moderated in 2024. The product retained its core breast-cancer business, but its opportunity in urothelial cancer contracted after Gilead withdrew the U.S. indication following failure of the confirmatory phase 3 TROPiCS-04 study to demonstrate the required clinical benefit.[6]
The central commercial question is whether TRODELVY can move earlier in treatment. Earlier-line breast-cancer use would expand patient volume, but it would also place the product in direct competition with Enhertu and other antibody-drug conjugates.
What FDA indications does TRODELVY have?
TRODELVY is approved in the United States for two main breast-cancer uses.
| Indication |
FDA status |
Treatment setting |
| Metastatic triple-negative breast cancer |
Regular approval |
Patients who received at least two prior systemic therapies, including at least one for metastatic disease |
| HR-positive, HER2-negative metastatic breast cancer |
Accelerated approval |
Patients who received endocrine-based therapy and at least two additional systemic treatments |
The original triple-negative breast-cancer approval was granted in April 2020 under the accelerated-approval pathway and converted to regular approval in April 2021 after confirmatory evidence supported clinical benefit.[5]
The HR-positive, HER2-negative indication was based primarily on the phase 3 TROPiCS-02 study, which showed improved progression-free survival and overall survival compared with physician's-choice chemotherapy in a heavily pretreated population.[7]
The FDA withdrew the urothelial-cancer indication in 2024 after the required confirmatory study failed to establish benefit. That withdrawal removed one of the product's key non-breast-cancer growth opportunities.[6]
How large is the TRODELVY market opportunity?
The largest current opportunity is metastatic breast cancer, particularly triple-negative disease and later-line HR-positive, HER2-negative disease.
TRODELVY uses an anti-Trop-2 antibody linked to SN-38, the active metabolite of irinotecan. Trop-2 is expressed across several epithelial cancers, including breast, urothelial, lung, and gynecologic tumors. This creates a broad biological rationale, but clinical success has varied by tumor type.
Main commercial growth levers
-
Earlier-line breast-cancer treatment
Use in first-line or second-line metastatic disease could materially increase treated patients and duration of therapy.
-
Combination regimens
Gilead is evaluating TRODELVY with immune checkpoint inhibitors and other targeted agents. Successful combinations could improve treatment sequencing and reduce reliance on later-line chemotherapy.
-
Geographic expansion
The product has approvals in the United States, Europe, Japan, and other markets. Reimbursement timing and diagnostic practice differ materially by country.
-
New solid-tumor indications
Lung, endometrial, ovarian, and other Trop-2-expressing tumors remain potential targets, although the urothelial setback increases the evidentiary burden for future expansion.
The principal limitation is that Trop-2 expression alone has not guaranteed clinical success. Patient selection, prior treatment exposure, tumor biology, and combination strategy determine whether an indication becomes commercially viable.
How does TRODELVY compare with Enhertu?
Enhertu is the most important direct competitive benchmark in breast cancer, although the products target different antigens.
| Attribute |
TRODELVY |
Enhertu |
| Developer and marketer |
Gilead Sciences |
Daiichi Sankyo and AstraZeneca |
| Active antibody target |
Trop-2 |
HER2 |
| Payload |
SN-38 |
Topoisomerase I inhibitor derivative |
| Core breast-cancer position |
Triple-negative and HR-positive/HER2-negative disease |
HER2-positive, HER2-low, and HER2-ultralow disease |
| Principal competitive issue |
Earlier-line breast-cancer positioning |
Expansion across HER2 expression levels |
| Key safety concern |
Neutropenia and diarrhea |
Interstitial lung disease/pneumonitis |
Enhertu has expanded the HER2 treatment market by demonstrating activity in HER2-low and HER2-ultralow breast cancer. That expansion places pressure on TRODELVY in patients whose tumors fall within overlapping late-line treatment pathways.
TRODELVY retains a strong position in triple-negative breast cancer, where Enhertu's role depends on HER2 expression. The competitive balance will increasingly be determined by head-to-head or closely comparable earlier-line trials rather than by target biology alone.
Other competitors include chemotherapy, pembrolizumab-based regimens in selected earlier-line triple-negative disease, and datopotamab deruxtecan, which received U.S. approval in 2025 for certain HR-positive, HER2-negative breast-cancer patients. The latter is a direct Trop-2 antibody-drug-conjugate competitor and raises the long-term risk of share erosion in the HR-positive market.
What patents protect TRODELVY?
TRODELVY is a biologic drug and is governed primarily by the Public Health Service Act and the Biologics Price Competition and Innovation Act. Biologic patents are generally reviewed through the Purple Book and BPCIA patent-exchange process rather than through the conventional small-molecule Orange Book framework.[8]
Public patent records associated with sacituzumab govitecan and its antibody-drug-conjugate technology include U.S. Patent Nos. 10,583,158 and 10,905,713. Related patent families cover antibody-drug-conjugate composition, linker-payload structures, antibody conjugation, and therapeutic use.[9-10]
Patent protection is layered:
| Protection layer |
Commercial relevance |
| Antibody-drug-conjugate composition |
Protects the sacituzumab govitecan conjugate and related structures |
| Linker and SN-38 payload chemistry |
Can create manufacturing and design-around barriers |
| Antibody sequence and binding properties |
Limits substitution with closely related constructs |
| Methods of treatment |
Covers use in specified cancers and treatment settings |
| Manufacturing processes |
Can protect conjugation, purification, and product-quality controls |
U.S. biologic reference-product exclusivity generally runs for 12 years from first licensure. Because TRODELVY was first licensed in April 2020, the principal statutory reference-product exclusivity period extends to approximately April 2032, subject to the specific FDA licensure record and any applicable regulatory adjustments.[5,8]
Patent terms may extend beyond the 12-year biologic exclusivity period. The commercial loss-of-exclusivity date will therefore depend on patent validity, enforceability, pediatric extensions, BPCIA litigation, and the timing of any biosimilar application.
When does TRODELVY lose exclusivity?
The earliest predictable U.S. biosimilar opportunity is constrained by the 12-year reference-product exclusivity period, which points to April 2032. Patent barriers may push effective competition later.
The practical timeline is:
| Event |
Estimated timing |
| First U.S. approval |
April 2020 |
| Twelve-year reference-product exclusivity |
Approximately April 2032 |
| Potential first biosimilar litigation window |
Before commercial launch, depending on application timing |
| Likely commercial competition |
2032 or later, subject to patent outcomes |
| Small-molecule generic pathway |
Not applicable |
No conventional generic can substitute for TRODELVY. A biosimilar applicant would need to file under the BLA pathway and establish biosimilarity. Interchangeability would require separate FDA treatment and could affect automatic substitution at the pharmacy level.
Are there Paragraph IV challenges to TRODELVY?
Paragraph IV certification applies to patents listed for approved drugs under the Hatch-Waxman framework. TRODELVY is licensed as a biologic under a BLA, so the relevant challenge mechanism is the BPCIA patent-information exchange and related patent litigation, not a conventional Paragraph IV filing.
Publicly reported information through 2024 did not identify a launched biosimilar or a major BPCIA litigation campaign against TRODELVY. The absence of a public challenge does not eliminate future risk. The product's complex ADC structure, clinical manufacturing requirements, and patent layering raise the cost of biosimilar development.
How strong is the TRODELVY patent estate?
The estate is stronger than a single composition patent but is not immune to challenge.
Strengths
- The product is a complex antibody-drug conjugate rather than a simple protein.
- Manufacturing consistency, conjugation ratio, linker chemistry, and payload distribution create technical barriers.
- Patent families can cover both the product and manufacturing process.
- Twelve-year biologic exclusivity delays the earliest U.S. biosimilar launch opportunity.
- Product-specific clinical experience may support physician retention even after biosimilar entry.
Weaknesses
- Antibody-drug-conjugate claims can face written-description, enablement, obviousness, and claim-construction challenges.
- A biosimilar does not need to copy every manufacturing step if it can demonstrate comparable quality and clinical performance.
- Method-of-use patents may be vulnerable when they cover broad cancer populations or treatment sequences.
- Competing ADCs can reduce commercial value before biosimilar erosion begins.
The main protection is the combination of regulatory exclusivity, product complexity, and layered patent coverage. No single patent should be treated as the entire exclusivity case.
Which companies are challenging TRODELVY commercially?
The competitive landscape includes established oncology companies and emerging ADC developers.
| Company |
Product |
Competitive relevance |
| Daiichi Sankyo and AstraZeneca |
Enhertu |
Strong competitor in HER2-positive, HER2-low, and HER2-ultralow breast cancer |
| AstraZeneca and Daiichi Sankyo |
Datopotamab deruxtecan |
Direct Trop-2 ADC competition in HR-positive, HER2-negative disease |
| Merck and Seagen |
Keytruda and Padcev |
Important in urothelial cancer and combination-based treatment |
| Roche |
Tecentriq and other oncology products |
Checkpoint and targeted-therapy competition |
| Multiple biotech developers |
Trop-2 and other ADCs |
Longer-term threat in breast, lung, and gynecologic cancers |
The most serious threat is earlier-line displacement by products supported by stronger comparative data or better tolerability. Biosimilar competition is a later event.
What licensing deals affect TRODELVY?
Immunomedics had established regional commercialization arrangements before its acquisition by Gilead. Gilead inherited and managed those relationships as part of the transaction.
The most important geographic arrangement involved Everest Medicines for development and commercialization rights in Greater China. Regional partners can accelerate regulatory access, but they also reduce the revenue retained by Gilead and introduce local pricing and execution risks.
Gilead's acquisition of Immunomedics was itself the decisive licensing and control event. The $21 billion transaction reflected the expected value of TRODELVY's approved breast-cancer market and its potential in additional Trop-2-expressing tumors.[11]
What generic-entry risks exist for TRODELVY?
The near-term risk is competitive substitution, not generic entry.
Near-term risk: market share
- Enhertu can capture patients with HER2-low or HER2-ultralow disease.
- Datopotamab deruxtecan can compete directly for Trop-2-driven treatment.
- Earlier-line regimens can reduce the number of patients reaching TRODELVY's current later-line indications.
- Treatment guidelines can shift rapidly after positive comparative trials.
Medium-term risk: clinical differentiation
If TRODELVY fails to show superior efficacy or tolerability in earlier treatment settings, its market may remain concentrated in later-line disease. That would limit patient duration and revenue expansion.
Long-term risk: biosimilar entry
A biosimilar could pressure price and contracting terms after the biologic exclusivity period. The impact would depend on automatic substitution rules, payer formularies, provider confidence, and the number of competing biosimilars.
What is the outlook for TRODELVY revenue?
The base case is continued growth at a slower rate than during 2022 and 2023. A reasonable commercial framework is:
| Scenario |
Key assumptions |
Revenue implication |
| Upside |
Earlier-line breast-cancer success, effective combinations, additional solid-tumor approvals |
Sustained multi-billion-dollar potential |
| Base case |
Stable triple-negative use, gradual HR-positive adoption, limited new indications |
Continued blockbuster sales with moderate growth |
| Downside |
Earlier-line trial setbacks, share loss to Enhertu or datopotamab deruxtecan, no replacement for urothelial opportunity |
Plateau or decline from current sales |
The acquisition economics remain demanding. At $21 billion, Gilead paid a strategic premium for a product that was already approved but had significant expansion risk. The return depends on durable breast-cancer sales and successful use beyond the original late-line triple-negative setting.
Key Takeaways
- TRODELVY sales reached approximately $1.1 billion in 2024 after passing $1 billion in 2023.
- Breast cancer is the commercial foundation; the urothelial-cancer withdrawal reduced diversification.
- The main competitive threat is Enhertu in overlapping breast-cancer populations and datopotamab deruxtecan in Trop-2-targeted treatment.
- TRODELVY's U.S. biologic exclusivity points to approximately April 2032, with patent protection potentially extending beyond that date.
- Conventional Paragraph IV generic litigation is not the relevant pathway because TRODELVY is a BLA biologic.
- The strongest growth catalyst is earlier-line breast-cancer adoption.
- The largest financial risk is clinical underperformance in earlier-line trials, which could leave TRODELVY concentrated in lower-volume later-line treatment.
FAQs
Is TRODELVY a blockbuster drug?
Yes. TRODELVY generated more than $1 billion in annual sales in 2023 and approximately $1.1 billion in 2024.
Who owns the TRODELVY patent rights?
Gilead Sciences owns and commercializes TRODELVY after acquiring Immunomedics in 2020. Patent rights include product, antibody-drug-conjugate, therapeutic-use, and manufacturing-related families.
Can a generic company make TRODELVY?
A conventional generic cannot use the Hatch-Waxman ANDA pathway. A competitor would need to pursue the FDA biosimilar pathway for the biologic reference product.
What cancer is the largest market for TRODELVY?
Metastatic breast cancer is the largest market, with established use in triple-negative disease and an approved later-line use in HR-positive, HER2-negative disease.
Will Enhertu replace TRODELVY?
Enhertu will compete for overlapping breast-cancer patients, particularly those with HER2-low or HER2-ultralow tumors. It is unlikely to replace TRODELVY across all patients because the products have different targets and approved treatment populations.
References
- Gilead Sciences, Inc. (2022). Annual report 2021.
- Gilead Sciences, Inc. (2024). Annual report 2023.
- Gilead Sciences, Inc. (2025). Annual report 2024.
- Gilead Sciences, Inc. (2025). Fourth-quarter and full-year 2024 earnings.
- U.S. Food and Drug Administration. (2023). Trodelvy prescribing information and approval history.
- U.S. Food and Drug Administration. (2024). Withdrawal of the urothelial-carcinoma indication for Trodelvy.
- Rugo, H. S., Bardia, A., Marmé, F., et al. (2022). Sacituzumab govitecan in hormone receptor-positive/HER2-negative advanced breast cancer. The Lancet, 400(10359), 1775-1785.
- U.S. Food and Drug Administration. (2024). Purple Book: database of licensed biological products.
- U.S. Patent and Trademark Office. (2020). U.S. Patent No. 10,583,158.
- U.S. Patent and Trademark Office. (2021). U.S. Patent No. 10,905,713.
- Gilead Sciences, Inc. (2020). Gilead to acquire Immunomedics for $88 per share in cash.
